NEW YORK (GenomeWeb News) – Invitrogen today said that it had non-exclusively licensed its patents covering the random prime amplification of nucleic acids to Qiagen, New England Biolabs, and Kirkegaard & Perry Laboratories.
 
The patents cover methods and kits used for “substantially” amplifying nucleic acids, Invitrogen said. The technology is used in common lab techniques, such as random prime labeling reactions, first-strand cDNA synthesis, and whole genome amplification.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Helix customers can purchase apps that interpret different aspects of their genome, Technology Review reports.

The New York Times reports that a number of companies and research institutes are pursuing gene therapies.

Salmon with shorter telomeres survive to make the trip back to their river homes, New Scientist reports.

In PLOS this week: vaginal microbiome composition, population patterns of Chagas-carrying Rhodnius ecuadoriensis, and more.